Figure 10.

GBS patient serum-derived anti-ganglioside Abs induce nodal but not axonal injury in wild-type animals with L5SNT. A, B, Immunofluorescent micrographs showing the paranodes stained by anti-Caspr Ab in sciatic nerves of control-serum-treated (A) and GBS-serum-treated animals (B) on postsurgical day 14. Scale bar, 20 μm. C, Quantitative ICC analysis shows that GBS serum-treated mice have significantly less number of nodes of Raniver at sciatic and tibial nerve levels than the control serum-treated nerves on postsurgical day 14. D, The significant reduction of CMAP amplitudes was observed in mice treated with GBS patient serum on postsurgical days 7 and 14 compared with the controls. E, The spread of Caspr staining along the paranodal axons can be found in GBS-serum-treated nerves. Scale bar, 10 μm. F, Morphometry shows that there is no significant difference in MF count in sciatic and tibial nerves between the control-serum-treated and GBS-serum-treated animals on postsurgical day 14. n = 6. *p < 0.05.